Status:
COMPLETED
Screening for Tuberculosis in HIV-infected Patients Eligible for Antiretroviral Treatment
Lead Sponsor:
Lund University
Collaborating Sponsors:
Swedish International Development Cooperation Agency (SIDA)
Conditions:
HIV Infection
Tuberculosis
Eligibility:
All Genders
18+ years
Brief Summary
Background: Increased access to antiretroviral therapy (ART) in Africa will require decentralization to primary health care. For this purpose, adapted methods for management of patients co-infected wi...
Detailed Description
Background: Tuberculosis (TB) remains as the leading opportunistic infection and cause of death among HIV-infected subjects in resource-limited settings (1). HIV infection is the strongest risk factor...
Eligibility Criteria
Inclusion
- HIV infection
- Fulfills criteria for antiretroviral therapy (CD4 cell count below 350 cells/ml and/or WHO stage IV)
- Residence in study uptake area
- Written informed consent to participation and to tracing in case of defaulting
Exclusion
- Ongoing or previous antiretroviral therapy
- Treatment for active tuberculosis for more than two weeks
Key Trial Info
Start Date :
October 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2015
Estimated Enrollment :
812 Patients enrolled
Trial Details
Trial ID
NCT01433796
Start Date
October 1 2011
End Date
December 1 2015
Last Update
March 8 2016
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Adama Health Centre
Ādama, Oromiya, Ethiopia
2
Geda Health Centre
Ādama, Oromiya, Ethiopia
3
Dhera Health Center
Dhera, Oromiya, Ethiopia
4
Mojo Health Centre
Mojo, Oromiya, Ethiopia